Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs)

@article{Hyttel1994PharmacologicalCO,
  title={Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs)},
  author={John Hyttel},
  journal={International Clinical Psychopharmacology},
  year={1994},
  volume={9},
  pages={19–26}
}
  • J. Hyttel
  • Published 1 March 1994
  • Psychology, Biology
  • International Clinical Psychopharmacology
Established antidepressants including tricyclic antidepressants (TCAs), tetracyclic antidepressants and monoamine oxidase inhibitors (MAOIs) affect a series of neurotransmitter functions. In the debate of clinical efficacy much attention has focused on the uptake of noradrenaline (NA) and serotonin (5-HT) as a means to increase neuronal activity. Most antidepressants, whether classic or new, inhibit the uptake of either one or the other or both transmitters. Besides that, all of the classical… 

Strategies to Optimize the Antidepressant Action of Selective Serotonin Reuptake Inhibitors

Unlike TCAs, the SSRIs display little affinity for aminergic receptors and therefore lack the severe side effects associated with the use of the former agents, which results in both an improved quality of life for the patients and greater treatment compliance, which is compromised in some instances by theUse of TCAs.

Enhanced selective serotonin re-uptake inhibitors as antidepressants: 2004 – 2006

Despite mixed results from clinical trials with several NK1 antagonists, effective therapeutic agents for depression may still emerge from compounds with combined serotonin reuptake inhibitor/NK1 antagonist properties.

Pharmacokinetics of selective serotonin reuptake inhibitors: clinical relevance.

Knowing about pharmacokinetic profiles of SSRIs will enable clinicians to predict and make appropriate dose adjustments to avoid potential drug-drug interactions that otherwise could result in toxicity.

Implication of 5-HT2 receptor subtypes in the mechanism of action of antidepressants in the four plates test

The results strongly suggest that activation of 5- HT2A receptors is critically involved in the anxiolytic activity of paroxetine, whereas the 5-HT2A and 5-ht2B receptors are involved inThe anti-punishment action of venlafaxine in the FPT.

Paroxetine: a review.

Paroxetine is well tolerated and effective in the treatment of both depressive and anxiety disorders across the age range and by comparison with tricyclic antidepressants (TCAs) has, therefore, a reduced propensity to cause central and autonomic side effects.

Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalon and frontal cortex

Results do not support the hypothesis that compared to SSRIs, compounds which inhibit both 5-HT and noradrenaline reuptake have a larger acute effect on extracellular 5- HT, and the effects of acute systemic administration of several SNRIs andSSRIs are compared.

Sertraline, a selective serotonin reuptake inhibitor modulates extracellular noradrenaline in the rat frontal cortex

The lack of an effect on NA release following a challenge with the α2-antagonist idazoxan suggests that chronic drug treatment has reduced the number of cortical pre-synaptic α1-adrenoceptors, activation of which would normally inhibit further NA release.

Modulation of extracellular noradrenaline in rate cortex by selective serotonin reuptake inhibitors (SSRIs).

Results suggest that neurones which survive DSP-4 treatment have a greater rate of noradrenaline release, and that fluoxetine, citalopram or desipramine were acting at a site on serotonergic neurones, which could contribute to the efficacy of antidepressants.

Duloxetine pharmacology: profile of a dual monoamine modulator.

Preclinical studies and existing data suggest that duloxetine is a novel and effective antidepressant.

Noradrenaline and serotonin reuptake inhibition as clinical principles:a review of antidepressant efficacy

  • M. Humble
  • Psychology, Biology
    Acta psychiatrica Scandinavica. Supplementum
  • 2000
The novel selective NRI reboxetine has been shown to be at least as effective as imipramine, desipramines and fluoxetines in the treatment of major depression and may also improve social functioning significantly more than fluoxettine providing a better quality of the remission.
...